-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $8

Benzinga·12/08/2025 10:35:06
Listen to the news
Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7.75 to $8.